Investor Presentation Full Year 2021

4 Investor presentation Full year 2021 Novo NordiskⓇ Strategic Aspirations 2025 | Highlights full year 2021 Purpose and sustainability Commercial execution Adding value to society: Medical treatment provided to 34.6 million people living with diabetes in 2021 46 new vulnerability assessments conducted enabling access to insulin to ~82,000 people with diabetes Reaching 18 countries and around 32,000 children in Changing Diabetes in Children Progress towards zero environmental impact: 43% reduction in CO2 emissions compared to 2019 Evolve culture and ensure distinct core capabilities: Launch of an aspirational gender diversity target Diabetes value market share increased by 0.8 percentage point to 30.1%¹ Obesity care sales increased by 55% at CER to DKK 8.4 billion Biopharm sales increased by 4% at CER to DKK 19.2 billion therapeutic focus Innovation and Financials . • Diabetes care: Blue indicates developments in Q4 2021 Resubmission of sema 2.0 mg in the US and approval in the EU Obesity care: Approval of WegovyⓇ, sema 2.4 mg, in the US and EU Strengthen and progress biopharm pipeline • . SogroyaⓇ phase 3 programme in children with growth hormone deficiency successfully completed First Mim8 phase 1/2 trial cohorts successfully completed Other serious chronic disease: Phase 3a development initiated with ziltivekimab in CVD and semaglutide in NASH and Alzheimer's disease Acquisition of Dicerna Pharmaceuticals and its RNAi platform to be applied across therapy areas Sales growth of 14% and Operating profit growth of 13%: . . Sales in International Operations grew by 14% . Sales in the US grew by 13% with 60% of sales came from products launched since 2015 Gross margin positively impacted by continued productivity gains in Product Supply Free cash flow of DKK 29.3 billion and DKK 41 billion returned to shareholders Total dividend of DKK 10.40 per share and payout ratio of 49.6% The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth. Note: Unless otherwise specified growth rates are at constant exchange rates 1 MAT (Moving Annual Total) value market share IO: International Operations; NAO: North America Operations; Sema: Semaglutide; NASH: Non-alcoholic steatohepatitis; CVD: Cardiovascular disease; sema: semaglutide

View entire presentation